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Abstract
Atherosclerosis is a disease of chronic inflammation, characterized by a dysfunctional 
interplay between the immune apparatus and lipids. Immune cells, as well as nonim-
mune cells, drive plaque inflammation through a complex crosstalk of inflammatory 
mediators. The cells are activated by risk factor–induced triggers, which are present in 
the circulation and in the vessel wall, such as shear stress, oxidized lipoproteins and oxi-
dative stress. Without relief from risk factors, the activation of inflammatory processes 
persists, resulting in a chronic nonresolving inflammation. Inflammation is associated 
with severity of disease, and complex lesions, which are prone to rupture and cause acute 
events, are characterized by extensive inflammation. Thus, inflammation is an active 
driver of atherosclerotic plaque development and a risk factor for atherosclerotic events. 
It is therefore of utmost importance to understand the mechanisms behind these inflam-
matory processes and to be able to develop new diagnostics and treatment modalities for 
atherosclerotic disorders. This chapter provides a brief overview of the most important 
inflammatory players and processes during atherosclerotic plaque development and of 
possible therapeutic targets to combat atherosclerotic disease.
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1. Introduction
Atherosclerosis is a complex disease of the artery wall. It is the major cause of cardiovascular 
disease (CVD), which is the most common cause of death in the world, killing 17.5 million 
people each year [1]. Although previously thought of as a disorder of age and cholesterol, it 
is now commonly appreciated that atherosclerosis results from a complex interplay between 
inflammation and lipids. As early as in the nineteenth century, Rudolf Virchow described 
inflammation as an active driver of plaque development; however, the importance of these 
findings was not appreciated until over a century later. During this time, modern immunology 
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evolved extensively and paved the way for in-depth understanding of how the immune system 
works. Identification of adhesion markers on endothelial cells and thus the ability of leukocytes 
to migrate into atheromas gave plausibility of inflammation as a contributor in atherogenesis 
[2, 3]. Furthermore, findings showing that monocytes [4], and later on that vascular cells [5, 6], 
secrete inflammatory mediators were important evidence supporting this. These discoveries 
were followed by clinical proof in the 1990s. Immune activation in atherosclerotic plaques was 
identified [7], and myocardial infarction was recognized as a potent trigger of CRP release [8]. 
Since then, an extensive number of animal as well as clinical studies have established inflam-
mation as a major driver of atherosclerotic disease. Regardless of this acceptance, our under-
standing of atherogenic inflammation is far from complete.
2. Inflammatory mediators in atherosclerosis
The evidence for atherosclerosis as an inflammatory disease is solid. The importance of 
immune activation in atherosclerosis is demonstrated in several animal models, were removal 
of central inflammatory mediators or cell types have been shown to extensively reduce plaque 
development [9–11]. Further, both communicable and noncommunicable inflammatory condi-
tions increase the risk of cardiovascular disease (CVD), and CRP is an independent risk factor 
of cardiovascular events, both in healthy individuals and in patients with established disease 
[12–14]. Moreover, immune cells are present within all atherosclerotic plaques, from early fatty 
streaks to complex atheromas. Lesional inflammation increases during the course of plaque 
development and is most prominent in vulnerable plaques with large necrotic cores. Immune 
cells, but also smooth muscle cells, platelets and endothelial cells are drivers of plaque inflam-
mation. Further, there are numerous different inflammatory triggers contributing to the great 
complexity of atherosclerotic plaque inflammation.
2.1. Immune cells in atherosclerotic inflammation
2.1.1. Macrophages: linking lipid metabolism and inflammation in atherogenesis
Macrophages are involved in all stages of plaque development, and are the most important 
immune cell in atherogenesis. Monocytes originate from a common stem cell in the bone marrow 
and migrate to various tissues where they develop into tissue-specific macrophages. Although 
circulating monocytes are a heterogeneous population, it is not known if distinct monocyte sub-
types develop into specific macrophage subtypes in humans. Monocytes from the circulation 
are recruited to the intimal layer of an artery by chemokines (e.g., CCL2) and neuronal guidance 
molecules (e.g., ephrin-B2). Inside the plaque, the monocytes differentiate to macrophages and 
engulf modified lipids through scavenger receptors such as SR-A1 and CD36. These lipid-filled 
macrophages, called foam cells, have altered phenotype and immune function. The efferocy-
totic capacity (ability to clear apoptotic cells) is one of the functions affected, and as extensive 
cholesterol accumulation is also lethal to the cells, a necrotic core consisting of cell debris and 
lipids forms inside the lesion. Plaques with large necrotic cores are associated with an unstable 
plaque phenotype and are prone to rupture. Monocyte infiltration and foam cell formation are 
key elements in plaque development and provide the main link between lipid metabolism and 
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chronic inflammation. There is, however, not only the quantity but also the phenotype of the 
macrophages that is important to the fate of the plaque [15]. The terms M1 and M2 describe the 
“classical” activated macrophage induced by T helper cell (Th) 1 cytokine interferon (IFN) γ 
and the “alternatively” activated macrophage induced by Th2 cytokines IL-13 and IL-4, respec-
tively. In short, the M1 macrophages produce pro-inflammatory cytokines and chemokines, 
cause tissue injury and promote atherosclerotic plaque development. M2 macrophages are often 
divided into “wound healing” and “regulatory” macrophages, the latter induced by immune 
complexes and IL-10, and produce anti-inflammatory cytokines and increase plaque stability 
[16]. Their pro- and antiatherogenic role is supported by studies showing that plaques enriched 
in M2 macrophages are associated with a stable or regressive phenotype and vice versa. Growth 
factors, lipids and cytokines produced by vascular cells and immune cells in the plaque affect 
the macrophage polarization state. Due to the complexity of inflammatory stimuli present in the 
plaque, the terms “M1” and “M2” and “classical” and “alternative” are overly simplified, and it 
is more likely that there exists a range of overlapping phenotypes in the atherosclerotic lesions 
[15, 17–19].
2.1.2. Dendritic cells are professional antigen presenting cells in the plaque
Another cell of the innate immune system, with great importance for atherosclerotic plaque 
inflammation, is the dendritic cell (DC). Increased number of DCs is present in atherosclerotic 
plaques of both humans and mice, and also, as described later, in tertiary lymphoid organs 
in the adventitia. However, the circulating number of DCs has, by the majority of studies 
performed, been reported to be reduced in atherosclerosis, which could reflect hampered 
production from the bone marrow as well as increased recruitment to the plaque [20–22]. As 
macrophages, the DCs engulf lipids and become foam cells, thereby contributing to plaque 
development. On the contrary, it has also been suggested that DCs can control cholesterol 
homeostasis and counteract hypercholesterolemia. It is, however, their role as antigen pre-
senting cells (APCs) that is most described in plaque inflammation [22]. Antigen presentation 
to T cells occurs both inside the plaque and in the lymphatic tissue, and it is shown that DCs 
can leave the atherosclerotic lesion upon signals from the chemokines CCL19 and CCL21 
[23]. The different subgroups of DCs activate pro- and anti-inflammatory functions in T cells. 
Difficulties in finding DC-specific markers, as well as the broad spectrum of different DC cell 
subtypes, have complicated the study of DCs in atherogenesis. There is, however, without 
doubt that DCs are important players in atherosclerotic disease [22, 24].
2.1.3. Other innate immune cells in atherogenesis
Neutrophils, mast cells and innate lymphoid cells, such as natural killer (NK) cells, are also 
important contributors to inflammation in atherogenesis, and their role is increasingly appre-
ciated. The description of these cell types is beyond the scope of this chapter, but has been 
reviewed elsewhere [25–28].
2.1.4. T-cell diversity in atherogenesis
CD4+ Th cells are the most abundant of the adaptive immune cells in the plaque and are there-
fore the most studied. In the plaque, they are activated by epitopes of native as well as oxidative 
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LDL presented by antigen-presenting cells (i.e., DCs). Activated T cells can affect atherosclerosis 
in two ways: through effector functions in the arterial wall and by activating B cells in lymphoid 
organs to produce circulating antibodies [29]. For CD4+ Th cells, several subsets have been 
identified. Most is known about the role of Th1 and Th2 in atherosclerosis; however, in recent 
years, it has become evident that Th17 and Tregs also are important players in atherogenesis. 
Polarization of Th cells is determined by the cytokine environment, and the proinflammatory 
Th1 cells are the most abundant T cell in the plaques. Th1 is characterized by secretion of IFN-γ, 
and Th2 typically secretes IL-4, IL-5 and IL-13. Th17 secretes IL-17 and IL-22, and Tregs secrete 
IL-10 and transforming growth factor (TGF)-β. In short, the Th1 cells are proatherogenic, while 
Tregs are atheroprotective. The impact of Th2, Th17 and natural killer T cells (NKTs) on athero-
sclerosis has shown more conflicting results, but are all present in the plaque. CD8+ cytotoxic T 
cells are also present in atherosclerotic lesions, although less frequent than CD4+ effector cells. 
Their activation and importance in atherosclerosis is not completely understood, but they can 
exert proatherogenic effects through IFN-γ production and macrophage activation or through 
their cytotoxic activity. Recently, the CD8+ regulatory T cell was described, with possible athero-
protective effects, through modulatory effects on T cell–B cell interaction [30, 31].
2.1.5. B cells and atherogenic antibodies
B cells are divided into two subtypes: B1 and B2 cells, and both of these are involved in athero-
genesis. B1 cells are involved in innate humoral immune response, divide upon self-renewal 
in the periphery and produce antibodies with low specificity. In contrast, B2 cells are conven-
tional B cells, which differentiate to plasma cells upon antigen presentation by T cells and DCs 
in lymph nodes, producing antibodies with high affinity and thereby contribute in adaptive 
immunity [30, 32]. Several animal models with B cell depletion resulting in aggravation of 
atherosclerosis have suggested a protective role for B cells in atherogenesis [33, 34]. Specific 
depletion of B2 cells has, however, been shown to reduce the development of atherosclerosis, 
suggesting subset specificity with regard to B cell atherogenity [35, 36]. In contrast to B2 cells 
which are mainly proatherogenic, producing IgG antibodies and activating T cells, B1 cells 
produce IgM antibodies, which can bind and thereby block the uptake of oxLDL by macro-
phages, exerting atheroprotective effects [37]. Most of these studies are performed in animal 
models, and thus, the importance for B cells in human atherosclerosis is unclear. In contrast to 
macrophages and T cells, B cells are only found in some atherosclerotic plaques, and a more 
abundant in so-called tertiary lymph organs, in the adventitial layer of the artery.
2.2. Tertiary lymphoid organs: extended plaque inflammation
During chronic inflammatory conditions, lymph-node–like structures, termed tertiary lymphoid 
organs (TLOs), can develop. Immune cells in the adventitial layer of atherosclerotic arteries were 
discovered decades ago [38], but the importance of these TLOs for atherosclerotic plaque inflam-
mation is still unknown. Advanced plaques are, however, associated with increased adventitial 
inflammation in both humans [39, 40] and Apoe−/− mice [41], suggesting that such extended 
plaque inflammation is important in the disease process. They likely evolve as a response to 
arterial wall inflammation in early lesion development. Medial SMCs are suggested as drivers 
of TLO development and are upon inflammatory stimuli shown to attract immune cells into 
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adventitia by production of the lymphorganogenic chemokines CXCL13 and CCL21 [42, 43]. 
The TLOs have a different composition of immune cells than the macrophage-rich plaques and 
is mostly composed of dendritic cells, T cells and a high number and diversity of B cells [43, 44]. 
This supports the role of TLOs as sites for T-cell training [45] and activation of local humoral 
immune responses [37]. A recent paper suggests that TLOs participate in atheroprotection [45], 
however, as the plaque itself, the TLOs can harbor both pro- and anti-inflammatory mediators, 
and thus, the net effect of adventitial inflammation is still elusive [46].
2.3. Inflammatory mechanisms of nonimmune cells in atherosclerosis
Plaque development does not occur randomly, but typically at curvatures and branching 
points in the arteries. At these sights, the shear stress activates the endothelial cells lining 
the arterial wall, leading to structural, molecular and functional alterations in the cells. 
Atheroprone flow activates the Nf-Kβ pathway and TLR2 expression in endothelial cells 
as well as a spectrum of other conduits leading to increased endothelial proliferation and 
inflammation. The activated endothelial cells adhere leukocytes and stimulate neighboring 
cells, e.g. vascular smooth muscle cells (VSMCs) [47–49]. Upon atherogenic stimuli, that 
is, from the activated endothelium, VSMCs undergo so-called phenotype switching. They 
progress from quiescent contractile to proliferative and migratory cells. These cells pos-
sess atheroprotective functions, as they produce extracellular matrix and proteoglycans, 
which protects the plaque from rupture. They do, however, also accumulate lipids and 
become macrophage-like foam cells, contributing to plaque development [50, 51]. Further, 
they express adhesion molecules such as VCAM-1 and ICAM-1 and thereby contribute to 
retention of monocytes and macrophages in the lesions [52, 53]. Thus, VSMCs can have 
both protective and destructive effects, depending on the stage of plaque development, and 
the stimuli present. Inflammatory monocytes can further stimulate VSMCs to secrete pro-
atherogenic matrix metalloproteinases (MMPs), which increase the risk of plaque rupture 
through thinning of the fibrous cap [54]. Further, VSMCs produce a variety of cytokines, 
activating immune cells, endothelial cells and other VSMCs in the lesion [51]. The inflam-
matory, atheroprone contribution of VSMCs is however probably under-communicated, 
as lack of cell-specific markers complicates their identification. Macrophages can express 
“classical” smooth muscle cell markers (i.e., α-actin and SM22α), and vice versa (i.e., CD68 
and Mac2), and this is determined by the presence of lipids and inflammatory stimuli in the 
plaque [55, 56]. The local inflammatory micro milieu will therefore decide the inflammatory 
contribution of smooth muscle cells to atherogenesis by regulating the transition of VSMC 
into inflammatory cells. Thus, there is a need for better markers to more correctly determine 
the role of VSMCs in atherosclerotic inflammation.
Also nonimmune cells in the circulation can contribute to the inflammatory milieu during 
atherogenesis. In addition to their most known roles as blood clotting cells, platelets also 
possess a great inflammatory potential. In a bidirectional manner, platelets interact with 
both leukocytes and endothelial cells to communicate inflammation. They express a variety 
of inflammatory mediators and receptors and contribute to atherosclerotic inflammation 
throughout disease development, from development of fatty streaks to thrombus formation. 
For an extensive review of the role of platelets in atherogenesis, see [57].
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3. Inflammasome activation: a central inflammatory driver of 
atherosclerosis
Inflammasomes are intracellular immune sensors, which are tightly controlled. They assem-
ble upon stimuli from tissue damage, infection or metabolic disturbances, and their activa-
tion results in production of the pro-inflammatory cytokines interleukin (IL)-1β and IL-18. 
There are several different inflammasomes, but the NOD-like receptor containing a pyrin domain 
3 (NLRP3) inflammasome is the most described and is an important constituent of innate 
immune apparatus. The NLRP3 inflammasome is a multimeric protein complex, which upon 
activation assembles and attracts caspase-1 molecules, which then is activated by self-cleavage. 
Active caspase-1 cleaves pro-IL⁻1β and pro-IL-18 to active cytokines ready for secretion [58, 59]. 
IL-1β is a prototypical proatherogenic cytokine, and NLRP3 is thus an important contributor 
to atherosclerotic inflammation. Cholesterol crystals, which deposit in atherosclerotic lesions, 
can activate the inflammasome both in vitro and in vivo [60, 61]. Further, the nonlipid danger 
signal ATP stimulates foam cell formation and cell migration through inflammasome activa-
tion [62]. Thus, the inflammasome promotes atherogenesis through inflammatory, as well as 
noninflammatory pathways, induced by lipid- as well as nonlipid stimuli. The NLRP3 inflam-
masome is present and activate in human atherosclerotic plaque [61]. Further, LDL receptor 
(LDLR)-deficient mice which received bone marrow from NLRP3-deficient mice show attenu-
ated atherosclerosis, and silencing of NLRP3 in ApoE-deficient mice stabilizes atherosclerotic 
plaques, pointing to an important role in atherosclerotic disease development [60, 63].
4. Danger signals in atherosclerosis
Inflammation is a part of the body’s response to harm, either from microbes, such as virus and 
bacteria, from burns or toxins, or from injury. The main function is to eliminate the insult, remove 
damaged tissue and restore tissue homeostasis. In atherosclerosis, the signals of harm, termed 
triggers, are numerous. In contrast to infectious disease, the most typical triggers in atherogen-
esis are however sterile. These are termed damage-associated molecular patterns (DAMPs) and 
are host-derived danger signals released upon tissue damage, metabolic disturbances, or envi-
ronmental stress. The risk factors of CVD include hyperlipidemia, smoking, hypertension and 
hyperglycemia, and all these factors cause DAMPs. There is, however, also evidence supporting 
a role for pathogens in atherosclerosis. These are termed pathogen-associated molecular pat-
terns (PAMPs). Bacterial and viral microbes are found in atherosclerotic plaques and are associ-
ated with disease risk [64, 65]. In addition to pathogens, gut microbiota is a potential source 
of PAMPs, also linked to atherogenesis [66]. The causal relationship between the endogenous 
DAMPs and atherosclerosis is stronger than for PAMPs. Microbes do not seem to be required for 
atherogenesis, as germ-free mice are not protected against disease [67]. The DAMPs comprehend 
the necessary evil of atherogenesis, namely lipids. As mentioned, the interaction between lipids 
and immune activation is the hallmark of atherosclerotic disease. Nonmodified fatty acids can 
activate immune responses, and while saturated fats are shown to stimulate inflammation, poly-
unsaturated fats are repressors [68]. It is, however, the modified lipids that are the typical triggers 
during atherogenesis. In hyperlipidemia, LDL undergoes oxidation, forming oxidation-specific 
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epitopes (OSEs), an important class of DAMPs in atherosclerosis [65, 69]. Cholesterol saturation 
inside the plaques leads to the formation of cholesterol crystals, which are important activators of 
the NLRP3 inflammasome (see Section 3) [60]. Other crystal structures can also serve as DAMPs, 
such as monosodium urate (MSU) crystals, which are composed of crystalized uric acid that 
contributes to the increased risk of atherosclerosis in patients with gout [70]. Moreover, lipids, 
nucleic acids and proteins can be modified in the presence of sugars, forming advanced glycation 
end products (AGEs), which activate immune responses through specialized receptors. These 
DAMPs are especially prevalent in diabetic subjects, promoting atherosclerosis through vascular 
dysfunction and increased inflammation [71, 72].
Necrotic cores of complex lesions are huge sources of inflammatory stimuli. In contrast to 
apoptosis, which is silent, necrosis and pyroptosis activate innate immune responses through 
the release of DAMPs such as heat shock proteins, nucleic acids, uric acid and ATP [65, 73, 74]. 
Further, as immune cells accumulate and the plaque develops, the demand for oxygen exceeds 
the availability, leading to hypoxic conditions. Hypoxia can activate the NLRP3 inflamma-
some and stimulate the polarization of M1 macrophages, causing increased inflammation in 
the plaques [75, 76]. Further, as mentioned, mechanical stress in the artery wall can also be a 
trigger of inflammation by stimulating endothelial activation, with subsequent activation of 
immune cells and VSMC in the artery wall.
The presence of risk factors provides continuous production of triggers, resulting in defective 
rescue mechanisms and persistent immune stimulation. Without relieve of these stimuli, a 
nonresolving inflammation develops, which is a hallmark of atherogenesis.
5. Defective resolution in atherosclerosis
Inflammation is a beneficial process; however, it becomes detrimental if the response is too 
strong or too long. Cessation of inflammation was previously thought of as a passive process; 
however, it is now known that resolution of inflammation is a highly active process, involv-
ing a complex network of mediators. For inflammation to stay homeostatic, these mecha-
nisms need to be intact. Atherosclerosis is characterized by a chronic nonresolving low-grade 
inflammation. Thus, a defective resolution of inflammation is an important contributor to 
atherosclerotic development and sustainability. Resolution is driven by endogenous spe-
cialized lipid-derived mediators (SPMs), which are synthesized from fatty acids, as well as 
proteins such as IL-10, M1 macrophages and the nucleotides inosine and adenosine. These 
stimulate tissue repair and regeneration and can therefore be distinguished from the clas-
sical anti-inflammatory signals, which are merely antagonists of pro-inflammatory signals. 
In a normal immune response, the production of SPMs is initiated by the production of the 
pro-inflammatory prostaglandins. Defective resolution in atherosclerosis can be summarized 
in three processes: (1) sustained inflammation, (2) increased infiltration/reduced egress of 
immune cells and (3) defective efferocytosis. In early atherosclerotic plaques, the efferocy-
totic capacity of macrophages (ability to clear apoptotic cells) is sufficient. Thus, inflamma-
tory cells are cleared from the lesion, and this process elicits the release of anti-inflammatory 
mediators that counteract the plaque development. In advanced plaques, the efferocytotic 
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capacity is however, as mentioned, compromised, leading to reduced clearance of dead cells, 
secondary necrosis and stimulation of the pro-inflammatory environment and growth of the 
necrotic core. SPMs are shown to counteract these processes and stabilize plaques [73, 77]. 
However, in advanced atherosclerotic lesions, the ratio of SPMs to pro-inflammatory media-
tors is decreased, and the administration of SPMs counteracts atherosclerotic disease develop-
ment. These findings provide a mechanistic explanation for the defective resolution observed 
in atherosclerotic disease [78, 79]. To further map the production, regulation and function of 
pro-resolving mediators in atherosclerosis will be of great importance to increase our under-
standing of how the inflammation in atherosclerosis becomes nonresolving.
6. Inflammation: a therapeutic target in atherosclerotic disease
Despite the great success of modern treatment modalities, atherosclerosis is still the leading 
cause of mortality and morbidity worldwide. For example, high-dose statin treatment and 
other standard measures only prevent a fraction of recurrent events in survivors of MI. This 
residual burden of events presents a pressing unmet medical need, and novel perspective 
on atherogenesis is needed to treat those who are not met by the current treatment regimes. 
An interesting new therapeutics is the enzyme proprotein convertase subtilisin-kexin type 
9 (PCSK9) inhibitors. PCSK9 binds to the hepatic low-density lipoprotein (LDL) receptor, 
thereby inhibiting recycling of this receptor, resulting in attenuated removal of LDL cho-
lesterol (LDL-C) from the circulation. The importance of PCSK9 for LDL-C homeostasis is 
illustrated in individuals with loss- and gain-of function mutations in this enzyme leading 
to hypo- or hypercholesterolemia, respectively, with dramatic effects on the incidence of ath-
erosclerotic disease. Recent studies have shown that anti-PCSK9 therapies markedly reduce 
LDL-C levels, leading to lower incidence of adverse cardiovascular disease (CVD) outcomes 
in high-risk patients with hyperlipidemia [80]. In patients with LDL levels that remain above 
the treatment target, despite statin treatment (residual LDL risk); adding a PCSK9 inhibi-
tor should be considered. Recent network meta-analysis demonstrates that PCSK9 inhibitors 
significantly reduce LDL cholesterol, on top of medium to high statin therapy [81]. Of direct 
relevance for inflammation, a very recent study, the CANTOS trial, suggests that those with 
residual inflammatory risk could benefit from interleukin-1β inhibition by Canakinumab. 
This anti-inflammatory treatment resulted in reduced cardiovascular risk, independent of 
lipid-lowering effects [82]. Another exciting approach to target inflammation in atheroscle-
rosis is the pro-resolving mediators SPMs. In contrast to anti-inflammatory agents, these 
ligands will not compromise host defense, one of the most important challenges of immuno-
suppressive therapeutics. Many experimental studies have shown therapeutic potential for 
SPMs; however, more knowledge is needed to pinpoint how these mediators act, before these 
findings can be translated into clinical use [83].
In sum, atherosclerosis is characterized by low-grade chronic inflammation in the arteries, in 
tight interplay with lipids. Targeting both pathways, depending on individual risk analysis, 
might be the future of prevention and treatment of cardiovascular disease. However, there is 
still a need for tools to identify people at risk, especially for personalized treatment. There is 
also a need to evolve more precise targets for treatment.
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Atherosclerotic plaque inflammation
Inflammation is involved in all stages of plaque development. Endothelial dysfunction allows 
entry of lipoproteins and migration of inflammatory cells into the intimal layer of the artery. 
Inside the plaque the cells are activated by PAMPs and DAMPs. Cholesterol crystals are impor-
tant DAMPs which can activate the NLRP3 inflammasome and stimulate release of inflamma-
tory cytokines. Further, accumulation of large amounts of lipids in the immune cells can lead to 
extensive cell death, and a necrotic core develops due to dysfunctional clearance of these cells. 
The necrotic core maintains the nonresolving inflammatory milieu in the lesion and is a typical 
feature of advanced plaques. Moreover, tertiary lymphoid organs can form in the adventitial 
layer of the vessel wall and feed the plaque with inflammatory cells and mediators, and can fur-
ther contribute to plaque inflammation. The authors wish to acknowledge Sverre Holm for mak-
ing the illustration and SERVIER Medical Art (www.servier.fr) for use of their medical art kits.
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